Category Archives: Pharmaceutical Industry

Pfizer gives up the chase.

Pfizer is saying today that it does not intend to extend a firm offer for AstraZeneca, bringing an end to its attempt to acquire the UK drug maker.  AZ shareholders were split on the latest offer, and a stumble by AZ would … Continue reading

Posted in Pharmaceutical Industry | Tagged , , | Leave a comment

China crackdowns squeeze pharma margins

From Reuters: A crackdown on corruption and pricing in China’s fast-growing pharmaceutical market has squeezed profits and margins, raising a red flag to global Big Pharma that the days of easy growth in the country may be over. Over the … Continue reading

Posted in Pharmaceutical Industry | Tagged , , | Leave a comment

More thoughts on drug company R&D productivity ranking

[updated]  Some comments I received on the previous post made me realize there was a more fundamental flaw in drug company R&D productivity rankings that should be highlighted. Drug discovery is by and large a high failure rate multistep process … Continue reading

Posted in Fixing Big Pharma Research, Pharmaceutical Industry | Tagged | Leave a comment

Who’s The Best In Drug Research? 22 Companies Ranked Incorrectly

Matt Herper at Forbes has a post on new pharmaceutical research productivity data from Richard Evans, a former Roche executive and Wall Street analyst.  Evans calculates metrics such as (1) Economic Returns to R&D spending, (2) Patents / $1M R&D spend, (3) Average … Continue reading

Posted in Fixing Big Pharma Research, Pharmaceutical Industry | Tagged , , | Leave a comment

Pfizer raises its bid for AstraZeneca – one last time?

Over the weekend, Pfizer finally made an official offer for AstraZeneca,  by raising its bid to $119B (15% higher than the last, unofficial, offer), and increasing the cash portion of the deal from 33% to 45%.  AZ had a market cap of … Continue reading

Posted in Pharmaceutical Industry | Tagged , , , | Leave a comment

Pfizer is a shark that can’t stop feeding

So says John LaMattina, a former head of research at Pfizer: The only way for a shark to survive is to keep going forward. To maintain its leadership, Pfizer will again need to make a major acquisition in the next … Continue reading

Posted in Pharmaceutical Industry | Tagged , , , , | Leave a comment

Consolidation in the Pharma industry continues unabated

As large assets swaps, mergers and acquisitions continue in the Pharma industry, Merck has announced it is selling its Consumer Care division to Bayer for $14B. The transaction will move Bayer into second place in consumer care, behind J&J. Merck … Continue reading

Posted in Pharmaceutical Industry | Tagged , , , | Leave a comment

Pfizer won’t take no for an answer

Amidst several indications that Pfizer will launch a hostile bid for AstraZeneca if necessary, this quote stands out: Asked whether hostile moves could hurt integration of the two companies, Chief Executive Ian Read said, “No, in my opinion, all it … Continue reading

Posted in Pharmaceutical Industry | Tagged , , , , | Leave a comment

Pharma companies consider selling off mature drug portfolios

As big shifts in the Pharmaceutical industry continue, Reuters is reporting that several large pharma companies, including Abbott, Merck and Sanofi, are considering selling off their portfolios of compounds that have lost patent protection.  From a pharma company’s perspective, branded … Continue reading

Posted in Pharmaceutical Industry | Tagged , | 1 Comment

Pfizer’s real strategy is (mostly) tax-minimization

   Many observers were initially left scratching their heads over Pfizer’s pursuit of AstraZeneca, a company that has had major pipeline troubles of its own.  As more information has come out, Pfizer’s strategy is beginning to make sense.  They aren’t pursuing an old-style mega … Continue reading

Posted in Pharmaceutical Industry | Tagged , , , , | 1 Comment